Startups

Pluvia Biotech

Pluvia Biotech is a University of Bergen spin-out developing medicines for rare genetic disorders caused by misfolded proteins. Its lead candidate, PBAS499, is an oral pharmacological chaperone designed to stabilize the phenylalanine hydroxylase enzyme and restore its activity in phenylketonuria (PKU), a metabolic disorder in which excess phenylalanine can damage the brain. The company is completing preclinical work and preparing for clinical development, while seeking to apply its protein-stabilization platform to other rare diseases. Pluvia AS is its Norwegian legal company.

Founded 2015

Team

Altanchimeg AltankhuyagResearcher

Ann Kari GrindheimDirector of Non-clinical Development

Aurora MartinezChief Technology Officer and Board Member

Birgitte Gangmark VillmoBoard Member

Deborah RamsdellChief Executive Officer

Hilde FurbergBoard Member

Karina Skjervheim PrestegårdSenior Scientist

Maija SlaidiņaBoard Member

Randi Elisabeth TaxtBoard Member

Sebastián González RodríguezResearch Technician

Sveinung HoleChairman of the Board

Torgeir VaageChief Financial Officer and Registered General Manager

Trond-André KråkenesResearch Technician

Willem van WeperenBoard Member

Øivind EngerDeputy Board Member

Investments

$—2026-05-19	Sarsia, Investinor
$—2026-02-25	0 participations
NOK 15M2025-11-25	0 participations
NOK 3M2017-12-06	Investinor, Sarsia

team@apexlogos.ai10 hours ago
Historical first Investinor/Sarsia Seed financing announced December 6, 2017: Investinor’s own Q4 2017 report identifies NOK 3.5m total financing, of which NOK 1m was Investinor’s actual individual investment, resulting in a 5.0% holding. Exact closing date and stage remain unknown. This is a separate historical investment, not the May 2026 seed extension. Source names Sarsia Seed as co-investor without a numbered fund allocation; no allocation guessed. Bergen Research Foundation and Bergen Technology Transfer are described as owners but no cash participation in this precise financing is proved. Sources: https://investinor.no/investinor-investerer-i-bioteknologiselskapene-aim-therapeutics-og-pluvia/ ; https://investinor.no/wp-content/uploads/Investinor-delarsrapport-4-kvartal-2017-2.pdf .
team@apexlogos.ai10 hours ago
Pluvia AS (Norwegian registry 916635559) is distinct from Turkish Pluvia Pharma. The issuer confirms a seed-extension announced May 19, 2026 involving Sarsia, Investinor, Mid Atlantic Bio Angels and Tidligfasekapital Vestland; amount and closing date unknown. New missing investors require full profiles before participation links. The February 25, 2026 NPKUA investment announcement is separate and its financial instrument is unspecified, so no assumed equity ticket or allocation into the May event. The November 25, 2025 NOK 15.6m IPN award is explicitly a grant, kept separate. No Sarsia fund allocation inferred. Deborah Ramsdell became CEO August 24, 2026; Willem van Weperen transitioned to board. Government registry retains Torgeir Vaage as legal general manager while issuer identifies him as CFO; these are recorded distinctly from Deborah’s current CEO role. Board roles with avregistrert=false only; Øivind Enger is an active deputy here. Sources: https://pluviabiotech.com/wp-content/uploads/2026/05/Press-release-Pluvia-Investment_19May2026.pdf ; https://pluviabiotech.com/wp-content/uploads/2026/02/Press-release-Pluvia-PBAS499-NPKUA_25Feb2026.pdf ; https://pluviabiotech.com/wp-content/uploads/2025/11/Press-release-Pluvia-PBAS499-IPN-Grant_25Nov2025.pdf ; https://pluviabiotech.com/wp-content/uploads/2026/08/Press-release-CEO-transition-Pluvia_24Aug2026.pdf ; https://data.brreg.no/enhetsregisteret/api/enheter/916635559/roller .